Theriva Biologics (TOVX) Other Non Operating Income (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Other Non Operating Income of $1000.0 for Q1 2026, up 133.33% year-over-year from $428.57 in Q1 2025, and up 120.0% quarter-over-quarter from -$5000.0 in Q4 2025.
Theriva Biologics (TOVX) Other Non Operating Income (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Other Non Operating Income for 10 consecutive years, with $1000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 133.33% year-over-year to $1000.0; the TTM figure through Mar 2026 stood at $30000.0 (up 104.15% YoY), while the FY2025 annual figure was $25000.0, up 103.47% from the prior year.
- Other Non Operating Income rose to $1000.0 in Q1 2026 per TOVX's latest filing, from -$5000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $20000.0 in Q2 2025 and bottomed at -$722000.0 in Q4 2024.
- Historically, Other Non Operating Income has averaged -$81294.1 across 5 years, with a median of -$3000.0 in 2025.
- On a YoY basis, Other Non Operating Income climbed as much as 2100.0% in 2025 and fell as far as 200.0% in 2025.
- Theriva Biologics' Other Non Operating Income stood at -$191000.0 in 2022, then slumped by 142.93% to -$464000.0 in 2023, then sank by 55.6% to -$722000.0 in 2024, then surged by 99.31% to -$5000.0 in 2025, then jumped by 120.0% to $1000.0 in 2026.
- Business Quant data shows TOVX's Other Non Operating Income at $1000.0 in Q1 2026, -$5000.0 in Q4 2025, and $14000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,000.00 |
| Mar 31, 2026 | 1,000.00 |
| Dec 31, 2025 | -5,000.00 |
| Sep 30, 2025 | 14,000.00 |
| Jun 30, 2025 | 20,000.00 |
| Mar 31, 2025 | -3,000.00 |
| Dec 31, 2024 | -722,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Jun 30, 2024 | -1,000.00 |
| Mar 31, 2024 | -1,000.00 |
| Dec 31, 2023 | -464,000.00 |
| Sep 30, 2023 | 6,000.00 |
| Jun 30, 2023 | -4,000.00 |
| Mar 31, 2023 | 6,000.00 |
| Dec 31, 2022 | -191,000.00 |
| Sep 30, 2022 | -9,000.00 |
| Jun 30, 2022 | -9,000.00 |
| Mar 31, 2022 | -23,000.00 |
| Jun 30, 2014 | 95,000.00 |
| Dec 31, 2013 | 47,000.00 |